



## Istodax® (romidepsin) – Indication withdrawal

- On August 2, 2021, [Bristol-Myers Squibb \(BMS\)](#) announced that the company plans to voluntarily withdraw the indication for [Istodax \(romidepsin\)](#) as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy.
  - Celgene, a wholly subsidiary of BMS, received FDA approval of this indication in 2011 through the accelerated approval pathway.
- The accelerated approval was based upon results from two clinical studies, assessing the effect of Istodax on the surrogate endpoint of overall response rate. BMS conducted a subsequent confirmatory phase 3 study evaluating Istodax plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs. CHOP in first line PTCL patients, but the trial did not meet the primary efficacy endpoint of progression free survival.
- Patients who are being treated with Istodax for PTCL should consult with their healthcare provider.
- Istodax is still approved for the treatment of cutaneous T-cell lymphoma in adult patients who have received at least one prior systemic therapy.
- Refer to the Istodax drug label for information regarding this indication and Istodax's other FDA approved indication.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.